Global Bioidentical Hormones Market
Bioidentical Hormones Market Size And Forecast
According to Verified Market Research, the Global Bioidentical Hormones Market was valued at USD 6.63 Billion in 2018 and is projected to reach USD 9.92 Billion by 2026, growing at a CAGR of 5.26% from 2019 to 2026.
Global Bioidentical Hormones Market Outlook
Over the past two decades, a trend has been witnessed wherein a majority of physicians have started shifting their interests in bioidentical hormones than their synthetic counterparts as the former offers less health risk as compared to the latter. They have started opting for bioidentical hormones for the treatment of symptoms related to menopause and to support overall health. In 2002, according to the reports published by the U.S. government-sponsored Women’s Health Initiative (WHI) reveal that the risks of non-bioidentical hormones (specifically Premarin and Provera) in HRT outweighed the benefits they offered. Therefore, growing health awareness among the female population is expected to drive market growth.
Global Bioidentical Hormones Market: Segmentation Analysis
The Global Bioidentical Hormones Market is segmented on the basis of Product Type, Type, End-User and geography.
Global Bioidentical Hormones Market Competitive Landscape
The “Global Bioidentical Hormones Market” study report will provide a valuable insight with an emphasis on global market including some of the major players such as – Noven Pharmaceuticals, Novartis AG, Sottepolle, BioTE Medical, Pfizer Inc., TherapeuticsMD Inc, Bayer AG, Novo Nordisk A/S, and Others.
Verified Market Research has been providing Research Reports, with up to date information, and in-depth analysis, for several years now, to individuals and companies alike that are looking for accurate Research Data. It has large database which includes the latest content from renowned authors and publications worldwide. It also provides customized Data and Reports according to the need of the client.